Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction
NCT ID: NCT02021760
Last Updated: 2016-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2013-05-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Trial Design: Placebo controlled randomized study with parallel groups
* Primary Endpoint: Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance (CMR) day 4-7
* Efficacy Parameters: Myocardial infarct size expressed as a percentage to the myocardium at risk determined by CMR at 6 months.
* Global left ventricular function determined by left ventricular ejection fraction determined by CMR.
* Microvascular obstruction determined by CMR day 4-7. Quantified ECV (extracellular volume) in left ventricular as myocardium at risk day 4-7 and remodelling parameters day 180.
* Safety Parameters: Major adverse cardiovascular events.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction
NCT02164695
Postconditioning in ST-elevation Myocardial Infarction
NCT00922675
Impact of Ischemic Post-conditioning
NCT04068116
Ischemic Postconditioning in STEMI Patients Treated With Primary PCI
NCT03787745
Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI)
NCT00865722
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Remote Ischemic per-postconditioning
Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if \>180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.
Primary Percutaneous Coronary Intervention
Primary Percutanous Coronary Intervention is performed in both Groups.
Sham
The sham procedures include application of the cuff around the thigh but it is not inflated.
Otheriwize normal primary PCI.
Primary Percutaneous Coronary Intervention
Primary Percutanous Coronary Intervention is performed in both Groups.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Primary Percutaneous Coronary Intervention
Primary Percutanous Coronary Intervention is performed in both Groups.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chest pain indicating myocardial ischemia with a duration \>30 minutes and \< 6 hours prior to randomization.
* ST elevations \>0.1 mV (\>0.2 mV in V2-V3) in \> two contiguous leads in V1-V6.
* Informed consent.
Exclusion Criteria
* Left Bundle Branch Block on ECG.
* Previous CABG
* Cardiac arrest
* Any contraindication for CMR.
* Clinical symptoms of claudication
* Treatment with glibenclamide or cyclosporine on admission.
* Any condition that may interfere with the possibility for the patient to comply with or complete the study protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
John Pernow
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Pernow
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Pernow, Professor
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital
Stockholm, , Sweden
Danderyds Hospital
Stockholm, , Sweden
Södersjukhuset
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECOND
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.